Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab
Discontinuation of natalizumab in patients with relapsing-remitting multiple sclerosis (RRMS) at risk of progressive multifocal leukoencephalopathy (PML) is associated with disease reactivation. Forty-two RRMS patients, who switched from an extended interval dose (EID) of natalizumab to ocrelizumab,...
Saved in:
Published in | Multiple sclerosis Vol. 27; no. 5; p. 790 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
01.04.2021
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Be the first to leave a comment!